港股早評:恆指微幅高開0.05%,科技股多數上漲,生物醫藥股再度活躍
隔夜美股三大指數均漲超1.3%,熱門科技股普漲,中概指數漲1.33%。昨日止跌反彈的港股三大指數微幅高開,恆指漲0.05%,國指漲0.03%,恆生科技指數漲0.15%。盤面上,大型科技股多數上漲,其中,快手漲2%,騰訊、網易、京東、小米均有漲幅,美團、百度、阿里巴巴飄綠;生物醫藥股再度活躍,泰格醫藥漲超4%,藥明康德、藥明生物、君實生物齊漲;AI概念股集體上漲,心動公司再度大漲8.55%,赤子城科技、萬國數據、第四範式紛紛上漲,紙業股、軍工股、光伏股、黃金股、中醫藥股多數上漲。另一方面,汽車股部分走低,蔚來跌近6%,比亞迪股份續跌3%,濠賭股、內險股、建材水泥股走低。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.